ANI Pharmaceuticals (NASDAQ:ANIP) Downgraded by StockNews.com to “Sell”

StockNews.com downgraded shares of ANI Pharmaceuticals (NASDAQ:ANIP) from a hold rating to a sell rating in a research report sent to investors on Tuesday morning.

Several other equities analysts have also recently weighed in on ANIP. Leerink Partnrs upgraded ANI Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, December 11th. Piper Sandler assumed coverage on ANI Pharmaceuticals in a research report on Friday, October 11th. They issued an “overweight” rating and a $68.00 price target for the company. Truist Financial lifted their price target on ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a research report on Tuesday, October 22nd. HC Wainwright reiterated a “buy” rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a research report on Monday, November 11th. Finally, Leerink Partners started coverage on ANI Pharmaceuticals in a research report on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 price target for the company. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $77.71.

ANI Pharmaceuticals Stock Performance

Shares of ANIP opened at $59.12 on Tuesday. The firm has a market cap of $1.24 billion, a PE ratio of -107.49 and a beta of 0.73. The stock’s fifty day moving average price is $56.42 and its two-hundred day moving average price is $58.62. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. ANI Pharmaceuticals has a 1 year low of $52.50 and a 1 year high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.09 by $0.25. The firm had revenue of $148.30 million for the quarter, compared to analyst estimates of $144.37 million. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The business’s revenue was up 12.5% on a year-over-year basis. During the same period in the previous year, the company posted $1.05 earnings per share. On average, equities research analysts forecast that ANI Pharmaceuticals will post 3.86 EPS for the current year.

Insider Transactions at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, CFO Stephen P. Carey sold 7,500 shares of the stock in a transaction that occurred on Tuesday, December 17th. The stock was sold at an average price of $55.79, for a total value of $418,425.00. Following the completion of the sale, the chief financial officer now owns 154,468 shares in the company, valued at approximately $8,617,769.72. This trade represents a 4.63 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Krista Davis sold 1,000 shares of the stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $60.00, for a total value of $60,000.00. Following the completion of the sale, the senior vice president now owns 49,059 shares of the company’s stock, valued at approximately $2,943,540. This trade represents a 2.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 42,381 shares of company stock worth $2,441,556. 12.70% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in ANIP. KBC Group NV lifted its stake in shares of ANI Pharmaceuticals by 89.2% in the 4th quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company’s stock valued at $70,000 after purchasing an additional 600 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its position in ANI Pharmaceuticals by 24.2% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company’s stock valued at $177,000 after buying an additional 579 shares in the last quarter. HighTower Advisors LLC bought a new position in ANI Pharmaceuticals during the 3rd quarter valued at approximately $222,000. Susquehanna Fundamental Investments LLC bought a new position in ANI Pharmaceuticals during the 2nd quarter valued at approximately $228,000. Finally, China Universal Asset Management Co. Ltd. increased its position in ANI Pharmaceuticals by 64.2% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 4,045 shares of the specialty pharmaceutical company’s stock valued at $241,000 after buying an additional 1,582 shares in the last quarter. Hedge funds and other institutional investors own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.